The products covered by the agreement include GSK’s entire dermatology portfolio, certain anti-infective products and smoking cessation aid Zyban. The dermatology portfolio includes Betnovat, one of the Swedish market’s leading products for the treatment of eczema and psoriasis. Among the anti-infective products is Relenza, used in the treatment and prophylaxis of influenza.
The agreement principally embraces products which are well known and well established in the Swedish market. An exception is Altargo, a brand new antibacterial ointment for the treatment of impetigo and infected small wounds.
Lars Adlersson, CEO of Medivir, said: “During the coming years, Medivir intends to expand its product portfolio by additional co-promotion agreements with other companies, in licensing, acquisitions and internally developed products.”